Efficacy of Sunitinib in Elderly Patients with Metastatic Renal
Cell Carcinoma: Data from Real-World Clinical Practice

J 2016

Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice

POPRACH, Alexandr; Radek LAKOMÝ; Zbyněk BORTLÍČEK; Bohuslav MELICHAR; Tomáš PAVLÍK et al.

Základní údaje

Originální název

Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice

Název česky

Efektivita Sunitinibu v léčbě starších pacientů s metastatickým nádorem ledviny: Data z klinické praxe

Autoři

Vydání

Drugs & Aging, Auckland, Adis International Ltd, 2016, 1170-229X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Nový Zéland

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.769

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/16:00088914

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1007/s40266-016-0390-1

UT WoS

000384433400005

EID Scopus

2-s2.0-84982273742

Klíčová slova anglicky

INTERFERON-ALPHA; SAFETY; CANCER

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 4. 2017 15:09, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Background Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study was to analyse efficacy and toxicity of sunitinib as the first-line targeted therapy of elderly mRCC patients. Patients and Methods The national RENal information system registry of mRCC patients treated with targeted agents in the Czech Republic was used as the data source. Of the 1315 patients treated with sunitinib as first-line targeted therapy, 1016 and 299 patients were aged < 70 and aeyen70 years, respectively. Results Elderly patients had a significantly longer interval from diagnosis to the initiation of therapy. Median progression-free survival was 10.8 months (95 % confidence interval 9.8-11.8) and 8.8 months (7.2-10.4) for patients aged < 70 and aeyen70 years, respectively (p = 0.321). Median overall survival was 31.9 months (27.9-35.9) and 26.3 months (21.3-31.2), respectively (p = 0.044). Significantly more elderly patients started on a reduced dose of sunitinib or discontinued the treatment prior to progression because of adverse events. Conclusions The differences in patient profile and dose-reduction rates point to a different approach in the management of older and younger patients in daily clinical practice. The lower dose intensity of sunitinib in the elderly population may have translated into inferior survival.

Návaznosti

NV15-34678A, projekt VaV

Název: Molekulární prognostické a prediktivní faktory u pacientů s metastatickým renálním karcinomem léčených tyrozinkinázovými inhibitory

Citovat

POPRACH, Alexandr; Radek LAKOMÝ; Zbyněk BORTLÍČEK; Bohuslav MELICHAR; Tomáš PAVLÍK; Ondřej SLABÝ; Rostislav VYZULA; Marek SVOBODA; Igor KISS; Hana STUDENTOVA; Milada ZEMANOVA; Ondrej FIALA; Katerina KUBACKOVA; Ladislav DUŠEK; Jana HORNOVA a Tomas BUCHLER. Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs & Aging. Auckland: Adis International Ltd, 2016, roč. 33, č. 9, s. 655-663. ISSN 1170-229X. Dostupné z: https://doi.org/10.1007/s40266-016-0390-1.

@article{1362733,
   author = {Poprach, Alexandr and Lakomý, Radek and Bortlíček, Zbyněk and Melichar, Bohuslav and Pavlík, Tomáš and Slabý, Ondřej and Vyzula, Rostislav and Svoboda, Marek and Kiss, Igor and Studentova, Hana and Zemanova, Milada and Fiala, Ondrej and Kubackova, Katerina and Dušek, Ladislav and Hornova, Jana and Buchler, Tomas},
   article_location = {Auckland},
   article_number = {9},
   doi = {https://doi.org/10.1007/s40266-016-0390-1},
   keywords = {INTERFERON-ALPHA; SAFETY; CANCER},
   language = {eng},
   issn = {1170-229X},
   journal = {Drugs & Aging},
   title = {Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice},
   volume = {33},
   year = {2016}
}

TY  - JOUR
ID  - 1362733
AU  - Poprach, Alexandr - Lakomý, Radek - Bortlíček, Zbyněk - Melichar, Bohuslav - Pavlík, Tomáš - Slabý, Ondřej - Vyzula, Rostislav - Svoboda, Marek - Kiss, Igor - Studentova, Hana - Zemanova, Milada - Fiala, Ondrej - Kubackova, Katerina - Dušek, Ladislav - Hornova, Jana - Buchler, Tomas
PY  - 2016
TI  - Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice
JF  - Drugs & Aging
VL  - 33
IS  - 9
SP  - 655-663
EP  - 655-663
PB  - Adis International Ltd
SN  - 1170229X
KW  - INTERFERON-ALPHA
KW  - SAFETY
KW  - CANCER
N2  - Background Although a significant proportion of patients with metastatic renal cell carcinoma (mRCC) are elderly, the data on the outcomes of targeted therapies in this population are limited. The aim of the present retrospective registry-based study was to analyse efficacy and toxicity of sunitinib as the first-line targeted therapy of elderly mRCC patients. Patients and Methods The national RENal information system registry of mRCC patients treated with targeted agents in the Czech Republic was used as the data source. Of the 1315 patients treated with sunitinib as first-line targeted therapy, 1016 and 299 patients were aged < 70 and aeyen70 years, respectively. Results Elderly patients had a significantly longer interval from diagnosis to the initiation of therapy. Median progression-free survival was 10.8 months (95 % confidence interval 9.8-11.8) and 8.8 months (7.2-10.4) for patients aged < 70 and aeyen70 years, respectively (p = 0.321). Median overall survival was 31.9 months (27.9-35.9) and 26.3 months (21.3-31.2), respectively (p = 0.044). Significantly more elderly patients started on a reduced dose of sunitinib or discontinued the treatment prior to progression because of adverse events. Conclusions The differences in patient profile and dose-reduction rates point to a different approach in the management of older and younger patients in daily clinical practice. The lower dose intensity of sunitinib in the elderly population may have translated into inferior survival.
ER  -

POPRACH, Alexandr; Radek LAKOMÝ; Zbyněk BORTLÍČEK; Bohuslav MELICHAR; Tomáš PAVLÍK; Ondřej SLABÝ; Rostislav VYZULA; Marek SVOBODA; Igor KISS; Hana STUDENTOVA; Milada ZEMANOVA; Ondrej FIALA; Katerina KUBACKOVA; Ladislav DUŠEK; Jana HORNOVA a Tomas BUCHLER. Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. \textit{Drugs \&{} Aging}. Auckland: Adis International Ltd, 2016, roč.~33, č.~9, s.~655-663. ISSN~1170-229X. Dostupné z: https://doi.org/10.1007/s40266-016-0390-1.

Přehled o publikaci